We categorize these molecules as "pathway-specific modulators" or PSM. CUE-102 focuses on Wilm's tumor-1 (WT1) as the tumor antigen. We refer to this derivative scaffold as Neo-STAT™. Hence, this approach may be more applicable to diseases with diverse unknown antigens. As of the date of this report, we have met all required Diligence Milestones. We have and will continue to actively protect our intellectual property. In addition, on May 30, 2018, the Right to Try Act was signed into law. Additional guidances are expected to be finalized by the FDA in the near term. It will overhaul the current system of approvals for clinical trials in the EU. Thereafter, the U.S. Supreme Court agreed to hear this case. Oral argument in the case took place on November 10, 2020. A ruling by the Court is expected sometime this year. This discussion highlights some of the risks that may affect future operating results. In addition, there is a natural transition period when a new CRO commences work. rely on sole sources of supply for the preclinical and clinical supply of materials. These licenses may not be available on acceptable terms, or at all. Any of these occurrences could prove materially harmful to our operations and business. There is increasing pressure on biotechnology companies to reduce healthcare costs. A broad range of legislative measures also have been introduced at the federal level. We are an "emerging growth company," or EGC, as defined in the JOBS Act. We currently have one securities and industry analyst providing research coverage.